SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants
View ORCID ProfileJohn Kubale, Charles Gleason, Juan Manuel Carreño, Komal Srivastava, PARIS Study Team, View ORCID ProfileAubree Gordon, Florian Krammer, Viviana Simon
doi: https://doi.org/10.1101/2022.03.28.22273068
John Kubale
1Department of Epidemiology, School of Public Health, University of Michigan, Michigan
Charles Gleason
2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Juan Manuel Carreño
2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Komal Srivastava
2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Aubree Gordon
1Department of Epidemiology, School of Public Health, University of Michigan, Michigan
Florian Krammer
2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Viviana Simon
2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Icahn School of Medicine at Mount Sinai, New York, NY, USA
4Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted March 30, 2022.
SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants
John Kubale, Charles Gleason, Juan Manuel Carreño, Komal Srivastava, PARIS Study Team, Aubree Gordon, Florian Krammer, Viviana Simon
medRxiv 2022.03.28.22273068; doi: https://doi.org/10.1101/2022.03.28.22273068
SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants
John Kubale, Charles Gleason, Juan Manuel Carreño, Komal Srivastava, PARIS Study Team, Aubree Gordon, Florian Krammer, Viviana Simon
medRxiv 2022.03.28.22273068; doi: https://doi.org/10.1101/2022.03.28.22273068
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2298)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11623)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3629)
- Geriatric Medicine (341)
- Health Economics (622)
- Health Informatics (2332)
- Health Policy (919)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3390)
- Nursing (193)
- Nutrition (512)
- Oncology (1777)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1013)
- Primary Care Research (410)
- Public and Global Health (6021)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)